IDEAYA Biosciences (IDYA) Metrics: History & Chart

IDEAYA Biosciences, Inc.(IDYA)

Biotechnology · South San Francisco, CA

$37.48-0.58 (-1.53%)

Delayed quote: Oct 6, 2026, 11:45 AM EDT

About IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.

South San Francisco, CA

145 employees

www.ideayabio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Yujiro S. Hata

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-0.42%
30D Total Return	-4.52%
YTD Total Return	+10.10%
1Y Total Return	+37.70%
3Y Total Return	+43.80%
5Y Total Return	+42.36%
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	+10.10%
2025	+34.51%
2024	-27.77%
2023	+95.82%
2022	-23.14%
2021	+68.86%
2020

CAGR TTM	+37.49%
CAGR 3Y	+12.87%
CAGR 5Y	+7.32%
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	N/A
PE Ratio Avg TTM	N/A
PE Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

All Metrics

IDYA Valuation Metrics

IDYA Stock Price Metrics

IDYA Dividend Metrics

IDYA Growth Rate Metrics

IDYA Discounted Cash Flow Metrics

IDYA Returns By Period

IDYA Yearly Returns

IDYA Average Annual Returns By Period (CAGR)

IDYA Revenue Metrics

IDYA PE Ratio Metrics

IDYA PS Ratio Metrics

IDYA PB Ratio Metrics

IDYA Price to Free Cash Flow Ratio Metrics

IDYA Debt to Equity Ratio Metrics

IDYA PEG Ratio Metrics

IDYA FCF Yield

IDYA Earnings Yield

IDYA EBITDA Yield

IDYA OCF Yield

IDYA EV/EBIT Ratio Metrics

IDYA EV/EBITDA Ratio Metrics

IDYA EV/Assets Ratio Metrics

IDYA EV/Sales Ratio Metrics

IDYA Current Ratio Metrics

IDYA Quick Ratio Metrics

IDYA ROIC Metrics

IDYA Return on Assets Metrics

IDYA Return on Equity Metrics

IDYA Net Profit Margin Metrics

IDYA Gross Profit Margin Metrics

IDYA Tax Rate Metrics

PS Ratio	14.97
PS Ratio Avg TTM	13.72
PS Ratio Avg 3Y	163.56
Current VS TTM Avg	+9.11%
Current VS 3Y Avg	-90.85%
Current VS 5Y Avg	-77.78%

PB Ratio	2.92
PB Ratio Avg TTM	2.81
PB Ratio Avg 3Y	2.91
Current VS TTM Avg	+4.00%
Current VS 3Y Avg	+0.27%
Current VS 5Y Avg	+11.04%

PFCF Ratio	15.37
PFCF Ratio Avg TTM	12.06
PFCF Ratio Avg 3Y	12.04
Current VS TTM Avg	+27.46%
Current VS 3Y Avg	+27.69%
Current VS 5Y Avg	+27.69%

Debt/Equity Ratio	0.02
Debt/Equity Ratio Avg TTM	0.03
Debt/Equity Ratio Avg 3Y	0.02
Current VS TTM Avg	-24.49%
Current VS 3Y Avg	+32.57%
Current VS 5Y Avg	+59.01%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	6.51%
FCF Yield Avg TTM	9.07%
FCF Yield Avg 3Y	9.10%
Current VS TTM Avg	-28.24%
Current VS 3Y Avg	-28.43%
Current VS 5Y Avg	-28.43%

Earnings Yield	N/A
Earnings Yield Avg TTM	N/A
Earnings Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	2.49
Ev/Assets Ratio Avg TTM	2.44
Ev/Assets Ratio Avg 3Y	2.55
Current VS TTM Avg	+1.93%
Current VS 3Y Avg	-2.52%
Current VS 5Y Avg	+12.81%

Ev/Sales Ratio	13.93
Ev/Sales Ratio Avg TTM	12.92
Ev/Sales Ratio Avg 3Y	153.75
Current VS TTM Avg	+7.81%
Current VS 3Y Avg	-90.94%
Current VS 5Y Avg	-77.92%

Current Ratio	10.45
Current Ratio Avg TTM	11.47
Current Ratio Avg 3Y	16.46
Current VS TTM Avg	-8.90%
Current VS 3Y Avg	-36.49%
Current VS 5Y Avg	-16.48%

Quick Ratio	10.45
Quick Ratio Avg TTM	11.47
Quick Ratio Avg 3Y	16.46
Current VS TTM Avg	-8.90%
Current VS 3Y Avg	-36.49%
Current VS 5Y Avg	-16.48%

ROIC	(17.68%)
ROIC Avg 3Y	(19.91%)
ROIC Avg 5Y	(18.47%)
Current VS 3Y Avg	+11.17%
Current VS 5Y Avg	+4.30%
Current VS 10Y Avg	+26.06%

ROA	(13.36%)
ROA Avg TTM	(4.61%)
ROA Avg 3Y	(6.28%)
Current VS TTM Avg	-189.97%
Current VS 3Y Avg	-112.85%
Current VS 5Y Avg	-133.02%

ROE	(14.60%)
ROE Avg TTM	(17.99%)
ROE Avg 3Y	(16.36%)
Current VS TTM Avg	+18.84%
Current VS 3Y Avg	+10.75%
Current VS 5Y Avg	+12.06%

Net Profit Margin	(74.75%)
Net Profit Margin Avg TTM	(696.01%)
Net Profit Margin Avg 3Y	(564.35%)
Current VS TTM Avg	+89.26%
Current VS 3Y Avg	+86.75%
Current VS 5Y Avg	+83.65%

Gross Profit Margin	(43.89%)
Gross Pft Margin Avg TTM	(379.08%)
Gross Pft Margin Avg 3Y	44.03%
Current VS TTM Avg	+88.42%
Current VS 3Y Avg	-199.68%
Current VS 5Y Avg	-195.59%

Tax Rate	0.00%
Tax Rate Avg 3Y	0.00%
Tax Rate Avg 5Y	0.00%
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	N/A